Effects of sacubitril/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy

Naoki Okumura, Pardeep S. Jhund, Jianjian Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor C. Shi, Karl Swedberg, Michael R. Zile, Scott D. Solomon, Milton Packer, John J V Mcmurray

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background - In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the angiotensin-converting enzyme inhibitor enalapril in patients with heart failure and reduced ejection fraction. We examined whether this benefit was consistent irrespective of background therapy. Methods and Results - We examined the effect of study treatment in the following subgroups: diuretics (yes/no), digitalis glycoside (yes/no), mineralocorticoid receptor antagonist (yes/no), and defibrillating device (implanted defibrillating device, yes/no). We also examined the effect of study drug according to β-blocker dose (≥50% and <50% of target dose) and according to whether patients had undergone previous coronary revascularization. We analyzed the primary composite end point of cardiovascular death or heart failure hospitalization, as well as cardiovascular death. Most randomized patients (n=8399) were treated with a diuretic (80%) and β-blocker (93%); 47% of those taking a β-blocker were treated with ≥50% of the recommended dose. In addition, 4671 (56%) were treated with a mineralocorticoid receptor antagonist, 2539 (30%) with digoxin, and 1243 (15%) had a defibrillating device; 2640 (31%) had undergone coronary revascularization. Overall, the sacubitril/valsartan versus enalapril hazard ratio for the primary composite end point was 0.80 (95% confidence interval, 0.73-0.87; P<0.001) and for cardiovascular death was 0.80 (0.71-0.89; P<0.001). The effect of sacubitril/valsartan was consistent across all subgroups examined. The hazard ratio for primary end point ranged from 0.74 to 0.85 and for cardiovascular death ranged from 0.75 to 0.89, with no treatment-by-subgroup interaction. Conclusions - The benefit of sacubitril/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent regardless of background therapy and irrespective of previous coronary revascularization or β-blocker dose.

Original languageEnglish (US)
Article number003212
JournalCirculation: Heart Failure
Volume9
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Heart Failure
Mineralocorticoid Receptor Antagonists
Morbidity
Enalapril
Mortality
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Equipment and Supplies
Digitalis Glycosides
Neprilysin
Angiotensin Receptors
Digoxin
Therapeutics
Hospitalization
Confidence Intervals
LCZ 696
Pharmaceutical Preparations

Keywords

  • heart failure
  • neprilysin
  • sacubitril/valsartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effects of sacubitril/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy. / Okumura, Naoki; Jhund, Pardeep S.; Gong, Jianjian; Lefkowitz, Martin P.; Rizkala, Adel R.; Rouleau, Jean L.; Shi, Victor C.; Swedberg, Karl; Zile, Michael R.; Solomon, Scott D.; Packer, Milton; Mcmurray, John J V.

In: Circulation: Heart Failure, Vol. 9, No. 9, 003212, 01.09.2016.

Research output: Contribution to journalArticle

Okumura, Naoki ; Jhund, Pardeep S. ; Gong, Jianjian ; Lefkowitz, Martin P. ; Rizkala, Adel R. ; Rouleau, Jean L. ; Shi, Victor C. ; Swedberg, Karl ; Zile, Michael R. ; Solomon, Scott D. ; Packer, Milton ; Mcmurray, John J V. / Effects of sacubitril/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy. In: Circulation: Heart Failure. 2016 ; Vol. 9, No. 9.
@article{643417ed52664b68b7d256494e469066,
title = "Effects of sacubitril/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy",
abstract = "Background - In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the angiotensin-converting enzyme inhibitor enalapril in patients with heart failure and reduced ejection fraction. We examined whether this benefit was consistent irrespective of background therapy. Methods and Results - We examined the effect of study treatment in the following subgroups: diuretics (yes/no), digitalis glycoside (yes/no), mineralocorticoid receptor antagonist (yes/no), and defibrillating device (implanted defibrillating device, yes/no). We also examined the effect of study drug according to β-blocker dose (≥50{\%} and <50{\%} of target dose) and according to whether patients had undergone previous coronary revascularization. We analyzed the primary composite end point of cardiovascular death or heart failure hospitalization, as well as cardiovascular death. Most randomized patients (n=8399) were treated with a diuretic (80{\%}) and β-blocker (93{\%}); 47{\%} of those taking a β-blocker were treated with ≥50{\%} of the recommended dose. In addition, 4671 (56{\%}) were treated with a mineralocorticoid receptor antagonist, 2539 (30{\%}) with digoxin, and 1243 (15{\%}) had a defibrillating device; 2640 (31{\%}) had undergone coronary revascularization. Overall, the sacubitril/valsartan versus enalapril hazard ratio for the primary composite end point was 0.80 (95{\%} confidence interval, 0.73-0.87; P<0.001) and for cardiovascular death was 0.80 (0.71-0.89; P<0.001). The effect of sacubitril/valsartan was consistent across all subgroups examined. The hazard ratio for primary end point ranged from 0.74 to 0.85 and for cardiovascular death ranged from 0.75 to 0.89, with no treatment-by-subgroup interaction. Conclusions - The benefit of sacubitril/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent regardless of background therapy and irrespective of previous coronary revascularization or β-blocker dose.",
keywords = "heart failure, neprilysin, sacubitril/valsartan",
author = "Naoki Okumura and Jhund, {Pardeep S.} and Jianjian Gong and Lefkowitz, {Martin P.} and Rizkala, {Adel R.} and Rouleau, {Jean L.} and Shi, {Victor C.} and Karl Swedberg and Zile, {Michael R.} and Solomon, {Scott D.} and Milton Packer and Mcmurray, {John J V}",
year = "2016",
month = "9",
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.116.003212",
language = "English (US)",
volume = "9",
journal = "Circulation. Heart failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Effects of sacubitril/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy

AU - Okumura, Naoki

AU - Jhund, Pardeep S.

AU - Gong, Jianjian

AU - Lefkowitz, Martin P.

AU - Rizkala, Adel R.

AU - Rouleau, Jean L.

AU - Shi, Victor C.

AU - Swedberg, Karl

AU - Zile, Michael R.

AU - Solomon, Scott D.

AU - Packer, Milton

AU - Mcmurray, John J V

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background - In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the angiotensin-converting enzyme inhibitor enalapril in patients with heart failure and reduced ejection fraction. We examined whether this benefit was consistent irrespective of background therapy. Methods and Results - We examined the effect of study treatment in the following subgroups: diuretics (yes/no), digitalis glycoside (yes/no), mineralocorticoid receptor antagonist (yes/no), and defibrillating device (implanted defibrillating device, yes/no). We also examined the effect of study drug according to β-blocker dose (≥50% and <50% of target dose) and according to whether patients had undergone previous coronary revascularization. We analyzed the primary composite end point of cardiovascular death or heart failure hospitalization, as well as cardiovascular death. Most randomized patients (n=8399) were treated with a diuretic (80%) and β-blocker (93%); 47% of those taking a β-blocker were treated with ≥50% of the recommended dose. In addition, 4671 (56%) were treated with a mineralocorticoid receptor antagonist, 2539 (30%) with digoxin, and 1243 (15%) had a defibrillating device; 2640 (31%) had undergone coronary revascularization. Overall, the sacubitril/valsartan versus enalapril hazard ratio for the primary composite end point was 0.80 (95% confidence interval, 0.73-0.87; P<0.001) and for cardiovascular death was 0.80 (0.71-0.89; P<0.001). The effect of sacubitril/valsartan was consistent across all subgroups examined. The hazard ratio for primary end point ranged from 0.74 to 0.85 and for cardiovascular death ranged from 0.75 to 0.89, with no treatment-by-subgroup interaction. Conclusions - The benefit of sacubitril/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent regardless of background therapy and irrespective of previous coronary revascularization or β-blocker dose.

AB - Background - In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the angiotensin-converting enzyme inhibitor enalapril in patients with heart failure and reduced ejection fraction. We examined whether this benefit was consistent irrespective of background therapy. Methods and Results - We examined the effect of study treatment in the following subgroups: diuretics (yes/no), digitalis glycoside (yes/no), mineralocorticoid receptor antagonist (yes/no), and defibrillating device (implanted defibrillating device, yes/no). We also examined the effect of study drug according to β-blocker dose (≥50% and <50% of target dose) and according to whether patients had undergone previous coronary revascularization. We analyzed the primary composite end point of cardiovascular death or heart failure hospitalization, as well as cardiovascular death. Most randomized patients (n=8399) were treated with a diuretic (80%) and β-blocker (93%); 47% of those taking a β-blocker were treated with ≥50% of the recommended dose. In addition, 4671 (56%) were treated with a mineralocorticoid receptor antagonist, 2539 (30%) with digoxin, and 1243 (15%) had a defibrillating device; 2640 (31%) had undergone coronary revascularization. Overall, the sacubitril/valsartan versus enalapril hazard ratio for the primary composite end point was 0.80 (95% confidence interval, 0.73-0.87; P<0.001) and for cardiovascular death was 0.80 (0.71-0.89; P<0.001). The effect of sacubitril/valsartan was consistent across all subgroups examined. The hazard ratio for primary end point ranged from 0.74 to 0.85 and for cardiovascular death ranged from 0.75 to 0.89, with no treatment-by-subgroup interaction. Conclusions - The benefit of sacubitril/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent regardless of background therapy and irrespective of previous coronary revascularization or β-blocker dose.

KW - heart failure

KW - neprilysin

KW - sacubitril/valsartan

UR - http://www.scopus.com/inward/record.url?scp=84988667458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988667458&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.116.003212

DO - 10.1161/CIRCHEARTFAILURE.116.003212

M3 - Article

C2 - 27618854

AN - SCOPUS:84988667458

VL - 9

JO - Circulation. Heart failure

JF - Circulation. Heart failure

SN - 1941-3297

IS - 9

M1 - 003212

ER -